In many species prolactin is of biological importance and has a major role in determining the deposition and mobilization of fat. In human physiology, outside pregancy, prolactin secretion is altered by increasing body weight in both children and adults. Prolactin in this circumstance appears to be marker of hypothalamic ± pituitary function: the prolactin response to insulin-hypoglycaemia, thyrotrophin releasing hormone stimulation and other stimulatory factors may be diminished. In addition, obesity alters the 24 h spontaneous release of prolactin with a generalised dampening of release. A number of explanations have been given as possible causes for these alterations, but it seems likely that they re¯ect obesity per se and are associated with hyperinsulinaemia. Weight reduction, with accompanying decrease in plasma insulin levels, leads to a normalization of prolactin responses in most, but not all, circumstances. To date, no molecular basis has been identi®ed which links prolactin with increasing body fatness, weight and appetite: new data suggests a possible link in obese men between fasting plasma prolactin and leptin concentrations.
Introduction
Among the hormones of the anterior pituitary, prolactin, with more than 85 documented functions in various vertebrate species, is by far the most versatile. Prolactin was ®rst discovered in 1928 based on its ability to cause lactation in pseudopregnant rabbits. The hormone was ®rst puri®ed in 1932, but it was not until 1971 that human prolactin was puri®ed and shown to be distinct from human growth hormone (HGH). 1 In the early 1980s the cDNA and gene for prolactin were cloned and sequenced and the prolactin gene de®ned as a member of a multigene family that includes HGH and chorionic somato-mammotrophin hormone. In the late 1980s, the cloning and characterization of Pit-I as a tissue speci®c transcativator of prolactin gene transcription enhanced understanding of pituitary cell development and prolactin gene regulation. The cloning of several forms of the prolactin receptor within the past few years has led to the recognition that the receptor is a member of a large family of haemopoetic cytokine receptors. The diversity of the prolactin receptor isoforms and the structural overlap with other receptors in the family may partly explain prolactin's bewildering array of biological actions. 2 
Heterogeneity of prolactin isoforms
Human pituitary prolactin has been detected in a diversity of protein isoforms including a glycosylated hormone. Human prolactin consists of 199 amino acid residues and migrates on reducing gels at an apparent molecular size of 23 kDa. A cleaved two-chain form has been detected in serum and pituitary preparations in man. This isohormone is the product of speci®c enzymatic cleavage resulting in 8 and 16 kDa chains held together with a single disulphide bond. Although the 16 kDa cleaved form can be produced in vitro as an artefact, there is convincing evidence for it to be physiologically signi®cant. Moreover, the 16 kDa has reduced detectability in some radioimmunoassays. 3 A glycosylated form of prolactin, which migrates at 25 kDa, has also been isolated from human pituitaries. The glycosylated hormone represents between 13% and 25% of prolactin in the human pituitry gland. 4 Fractionation of human serum by chromatography resolves prolactin into three immunoreactive peaks Ð 23 kDa, 48 ± 56 kDa and 150 kDa forms. 150 kDa prolactin demonstrates decreased receptor binding and biological activity: this may explain the phenomenon of sustained hyperprolactinaemia with minimal symptoms and normal menses.
Hormone mediated regulation of prolactin gene transcription (Table 1) Steroids have both positive and negative effects. Injections of oestrogen into rats result in a rapid increase in prolactin gene transcription. By contrast, glucocorticoids normally induce a negative transcriptional effect on the prolactin promoter. A variety of other hormonal stimuli act indirectly on the prolactin gene via intracellular second-messenger systems. Dopamine mediates its negative effect on prolactin gene transcription via a decrease in intracellular cAMP. Thyrotrophin releasing hormone (TRH) rapidly stimulates prolactin gene transcription through increases in intracellular calcium. 1 Physiological doses of insulin appear to stimulate prolactin secretion Ð the physiological signi®cance of this is uncertain.
Regulation of prolactin secretion
As with all pituitary hormones, prolactin is secreted episodically with a distinctive 24 h pattern. In normal human subjects there are about 14 pulses of prolactin secretion in 24 h with approximately one every 90 min. Superimposed on this pattern is a bimodal 24 h pattern of secretion with a major nocturnal peak beginning after sleep onset and peaking in mid-sleep. 5 Prolactin levels are at their lowest around noon. Stress is a potent releaser of prolactin with a signi®cantly greater increase observed in women compared with men. 6 This re¯ects the in¯uence of oestrogen on prolactin release both within lactotrophs and at the level of the hypothalamus. The pathways mediating stress-related prolactin release are unclear but opioid peptides, in particular b-endorphins, play a role. 7 In contrast, melanocyte-stimulating hormone (MSH) appears to inhibit stress-induced increases.
Neuroendocrine regulation of prolactin secretion
Although the exact molecular mechanisms controlling prolactin release are presently incompletely understood, a number of prolactin-releasing factors (PRF) and prolactin-inhibitory factors (PIF) have been identi®ed. The connections between the median eminence (ME) and the anterior pituitary are critical to the maintenance of physiological control over prolactin secretion. Dopamine, a catecholamine present in the ME and the hypophyseal portal blood, acts as the major physiological PIF via a direct action on the pituitary. 8 The central nervous system contains several dopaminergic pathways: the tuberoinfundibulardopaminergic (TIDA) system is the one that primarily regulates prolactin secretion. Its cell bodies are located in the arcuate nucleus of the medial basal hypothalamus and their terminals project to the ME and pituitary stalk. Dopamine is transported to the anterior pituitary lobe via the long hypophyseal portal vessels; dopamine is present in high concentrations in the posterior lobe and this source of dopamine also plays a role in inhibiting prolactin release. Dopamine has a series of speci®c isoreceptors but only the D2 receptor subtype is present on anterior pituitary cells. The cytoplasmic domain of the D2 receptor is linked to adenylate cyclase and dopamine binding results in a decreased adenylate cyclase activity.
TRH was the ®rst PRF to be identi®ed. TRH induces prolactin release by a direct action on the pituitary gland and TRH regulation of prolactin gene transcription. 9 The role of TRH in the physiological surges of prolactin is unclear. Vasoactive intestinal peptide (VIP) has also been shown to stimulate prolactin release in isolated pituitary glands by increasing prolactin mRNA, possibly by the induction of cAMP. 10 Serotonin, or its precursor 5-hydroxytryptophan, stimulates prolactin release by two possible mechanisms either by reducing the activity of TIDA neurons or by stimulating the release of PRFs. 11 
Prolactin secretion in obesity
In many species prolactin secretion is associated with growth and metamorphosis. In the white-throated sparrow, for example, prolactin appears to be one of the factors controlling migration and fat deposition. 12 Fat deposition is promoted or inhibited depending on the relation between the peak release of prolactin and that of corticosterone during the day. This, in turn, is dependent on day length. In the Syrian hamster, appropriately timed injections of prolactin and corticosterone during the day and night produce marked reductions in obesity and insulin resistance. 13 In man, an increase in maternal plasma prolactin is seen in girls following puberty at a time of fat deposition. 14 Furthermore, the circadian rhythm of pulsatile prolactin release is altered in adult obesity with a delay in the nocturnal rise being reversed by weight loss. 15 Evidence for an abnormality in the hypothalamic ± pituitary regulation of prolactin secretion comes from the ®nding of impaired responses to a variety of pharmacological stimuli. Two distinct patterns of release to insulin-induced hypoglycaemia may be seen in obesity (Figure 1 ). 16 In some obese subjects there is no prolactin response to symptomatic hypoglycaemia (prolactin`non-responders'), while in other equally obese subjects a normal response is seen (prolactin`responders'). It has been suggested that the impaired prolactin response results from a primary disorder of hypothalamic function because an impaired prolactin response persists in such women despite their subsequent attainment of nearly normal weight. 17 Furthermore, some obese children have been reported to show no prolactin response to hypoglycaemia. 18 Jung and colleagues 19 found no signi®cant rise of plasma noradrenaline to hypoglycaemia in obese subjects with an impaired prolactin response, although the adrenaline response remained unimpaired. This suggests that the hypothalamic alteration, which may occur in those with a propensity for obesity, not only involves the control of pituitary but also affects the control of the sympathetic nervous system. Some investigators report a normal prolactin response to intravenous TRH, which suggests normal anterior pituitary reserves, while others have reported impaired prolactin release suggestive of a broader abnormality of hypothalamic regulation. 16, 20 The prolactin response to TRH stimulation is impaired in prepubertal obese children. 21 Drugs which antagonize the action of dopamine cause a release of prolactin in man. Of these, metoclopramide crosses the blood ± brain barrier and the release of prolactin, following its intravenous injection, probably results from its action on both hypothalamic and pituitary dopaminergic receptors. 22 Domperidone, in contrast, does not cross the blood ± brain barrier and its prolactin releasing action is predominantly at the pituitary level. 23 Additional support for an abnormality of central neural pathways in some obese subjects is the ®nding that`nonresponders' have a prolactin release after metoclopramide which is signi®cantly less than obese`responders', but a comparable prolactin response to domperidone (Figure 2 ). 24 The composition of the diet may also alter the prolactin response to hypoglycaemia. 24 An isocaloric high carbohydrate diet impairs the prolactin response in obese subjects who previously had a normal response (ie`responders'), while an identical diet has no effect in normal weight subjects.
It has been suggested that a central de®ciency of serotonin or an alteration in dopaminergic pathways may be the explanation for altered prolactin secretion in obesity. Treatment of obesity with fen¯uramine, a centrally acting serotoninergic agonist, restores to normal impaired prolactin responses to intravenous TRH and an arginine infusion. 25, 26 Furthermore, naloxone does not alter the fen¯uramine-enhanced prolactin response to TRH, suggesting that the prolactin alterations are not the result of an interaction between central opioidergic and serotoninergic pathways. 27 Evidence for a possible alteration in dopaminergic control of prolactin in obesity comes indirectly from a study of weight loss in association with the normalisation of plasma prolactin in patients with prolactin secreting pituitary adenomas. 28 A clear relationship was seen between high prolactin levels and increased body mass: neither increased body weight nor recent weight gain could be attributed to tumoural mass effect on the central hypothalamic area. Moreover, there was a strong relationship between the occurrence of post-treatment weight loss and prolactin normalization.
There is evidence to suggest that hyperinsulinaemia may be an explanation for the impaired prolactin responses seen in obesity. Signi®cant associations are observed between increased insulin secretion and resistance and the prolactin release to insulin-hypoglycaemia ( Figure 3) . 29 In addition, an inverse correlation is observed between increasing upper body obesity (as measured by an increasing waist-to-hip ratio) and the prolactin response to hypoglycaemia. These ®ndings suggest that subtle alterations in hypothalamic function account for altered prolactin secretion found in some obese subjects, but the situation is compounded by the metabolic alterations associated with regional fat distribution.
Prolactin in obesity Ð a hormone worth revisiting
There are clearly many unanswered questions about the role of prolactin in obesity. There are no published reports on levels of different prolactin isoforms in obesity nor whether glycosylated hormone levels differ between obese and lean. The possibility of a genetic basis to altered prolactin secretion has not been excluded, although there have been no reports of associations between polymorphisms of the prolactin gene and obesity. A recent report has, however, suggested a possible association between variants of the ob (obesity) gene, body mass index and interactions with the dopamine D2 receptor gene, while variants of the D2 receptor gene have been linked to obesity and impulsive-addictive-compulsive behaviour. 30, 31 It is intriguing that a relationship has recently been found between fasting plasma leptin and prolactin concentrations in obese men, which suggests a possible role for prolactin in regulating fat deposition and possibly reproductive function. This relationship was not seen in women, presumably because of the in¯uence of circulating oestrogens (Table 2 ).
In conclusion, altered prolactin secretion in obesity appears to be a marker of hypothalamic ± pituitary dysfunction that may be explained by alterations in central dopaminergic and serotoninergic tone. Such changes in prolactin release are associated with peripheral hyperinsulinaemia and, in men, with fasting leptin concentrations. The latter relationship raises intriguing questions about a role for prolactin in fat deposition and fertility in obesity. Inverse relationship (P`0.01) between log prolactin area under curve to insulin-hypoglycaemia and log steady-state plasma glucose (SSPG) attained during a simultaneous intravenous infusion of insulin, dextrose and somatostatin. SSPG is a measure of insulin sensitivity. 
